News
EW
102.14
+1.31%
1.32
What Edwards Lifesciences Stock Beat And Raised Outlook Means For Shareholders
Simply Wall St · 3h ago
Edwards Lifesciences Earnings Call Signals Durable Growth
TipRanks · 1d ago
Edwards Lifesciences Q3 Earnings Call Highlights
NASDAQ · 1d ago
Edwards Lifesciences (EW) Could Be 21% Undervalued After Earnings Guidance And Trial Data
Simply Wall St · 2d ago
Interactive Brokers Group Moves Up In Analyst Rankings, Passing Edwards Lifesciences
NASDAQ · 2d ago
Oppenheimer Remains a Hold on Edwards Lifesciences (EW)
TipRanks · 2d ago
Edwards Lifesciences Is Maintained at Buy by UBS
Dow Jones · 3d ago
UBS Maintains Buy on Edwards Lifesciences, Raises Price Target to $118
Benzinga · 3d ago
Edwards Lifesciences Is Maintained at Overweight by JP Morgan
Dow Jones · 3d ago
Edwards Lifesciences Price Target Raised to $120.00/Share From $105.00 by JP Morgan
Dow Jones · 3d ago
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Edwards Lifesciences (EW) and PROCEPT BioRobotics (PRCT)
TipRanks · 3d ago
Edwards Life (EW) Q3 2026 Earnings Call Transcript
The Motley Fool · 3d ago
Edwards Lifesciences Is Maintained at Buy by Citigroup
Dow Jones · 3d ago
Edwards Lifesciences Price Target Raised to $117.00/Share From $110.00 by Citigroup
Dow Jones · 3d ago
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $117
Benzinga · 3d ago
Edwards Lifesciences (EW) Stock Looks Fully Priced On Cash Flow
Simply Wall St · 3d ago
Edwards Lifesciences Is Maintained at Outperform by Leerink Partners
Dow Jones · 3d ago
Edwards Lifesciences Price Target Raised to $112.00/Share From $101.00 by Leerink Partners
Dow Jones · 3d ago
Leerink Partners Maintains Outperform on Edwards Lifesciences, Raises Price Target to $112
Benzinga · 3d ago
More
Webull provides a variety of real-time EW stock news. You can receive the latest news about Edwards Lifesciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About EW
Edwards Lifesciences Corporation is a global structural heart company. The Company's work includes both surgical and transcatheter therapies. Its portfolio of repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves provides a set of treatment options to serve the diverse and complex patients in need. Its segment includes the United States, Europe, Japan, and the Rest of World. Its product categories include Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical. It provides transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. Its products include SAPIEN 3 Ultra RESILIA transcatheter heart valve, SAPIEN 3 Ultra transcatheter heart valve, SAPIEN 3 transcatheter heart valve and Alterra adaptive prestent. The TMTT category includes a PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system and others.